News Archives - Page 442 of 790

MondayAug 30, 2021 9:30 am

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Leveraging Data to Offer Patients, Drug Manufacturers, Researchers, Better Outcomes

Avricore Health recently announced that screening had begun at 15 select Shoppers Drug Mart Pharmacies The company intends to expand its rapid diagnostics to other parts of Canada, as well as the US, UK, and EU Avricore aims to use diagnostics to generate data that it can then use to make better decisions and create outcomes It hopes to be a tremendous contributor to the critical data pool that is going to make medicines cheaper, more effective, and get to patients quicker When Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) signed a master agreement with Shoppers Drug Mart Inc., Canada’s leading…

MondayAug 30, 2021 9:30 am

FinovateFall 2021, A Fintech Seminar To Be Held In The World’s Financial Capital

Date: September 13-15, 2021 Venue-The Marriott Marquis Times Square, New York- Virtual only access also available On September 13-15, 2021, the FinovateFall is being held at The Marriott Marquis Times Square, New York. Organizations, financial institutions, fintech industry leaders, and finance influencers are invited to attend the FinovateFall 2021, an event that can also be accessed virtually. The event will be attended by global influencers and thinkers of the finance arena who will share their valuable insights and strategies on the latest global trends. FinovateFall offers a robust platform for the fintech fraternity to establish connections and derive ideas to…

MondayAug 30, 2021 8:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Applications to Support Research Phase Programs, Strengthen IP Portfolio

Company’s nonprovisional patent application includes claims to compositions, methods to support certain elements of preclinical and research programs Two international patent applications will grant Cybin the right to file future national applications into treaty member jurisdictions Cybin portfolio consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies and 4 active drug programs Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is moving forward to progress and strengthen its IP portfolio by filing three patents this month. After receiving an international search report of its May 2021 Patent Cooperation Treaty (“PCT”) application, Cybin…

MondayAug 30, 2021 8:00 am

FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), Committed to Fighting Global Warming Through Carbon-Free Ammonia Production

Blue and green hydrogen are the two types of hydrogen fuel types being examined for primary use – blue is less expensive but has the potential for higher greenhouse gas production, green hydrogen uses renewable energy sources like solar and wind power and creates a cleaner fuel Toyota Motor Corp. has manufactured one of the first hydrogen fuel cell-powered vehicles (Mirai), but there are only a handful of refilling stations available in Britain and three in Australia Global green ammonia market size is expected to record a CAGR growth rate of 54% from 2020 to 2025. When combusted correctly, carbon-free…

MondayAug 30, 2021 5:55 am

DSG Global Inc. (DSGT), IMC Expand EV Line, Strengthen Position in Growing Market

Company is beginning to deliver vehicles on a grander scale IMC anticipates deliveries to individuals, fleets, dealers and government agencies during the second half of the year With each step forward, Imperium is seeing its dealer-candidate network of future dealers expand DSG Global (OTCQB: DSGT) and its automotive division, Imperium Motor Corp. (“IMC”), are taking significant steps forward as they strengthen their position in the growing market for smart new-energy vehicles. Imperium is working with two partners, Skywell Auto and Jonway Automotive Group, to offer 26 EV models for sale at both DSGT California facilities: the Fairfield Experience Center and…

FridayAug 27, 2021 1:28 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), At the Forefront of the Psychedelic Renaissance

Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposes The prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelics The 21st century has seen a surge in psychedelics research, a critical factor that has initiated a renaissance in this industry Tryp Therapeutics remains at the forefront of this renaissance with its commitment to identifying and developing clinical-stage compounds for diseases with high unmet medical needs, like Fibromyalgia and Eating Disorder…

FridayAug 27, 2021 1:14 pm

AmpliTech Group Inc. (NASDAQ: AMPG) Poised for Anticipated Growth in RF Communications Tech Component Market

Radio frequency (“RF”) technology designer and developer AmpliTech Group is leveraging this year’s Nasdaq uplisting and Russell Microcap Index placement to increase its market visibility AmpliTech builds and markets communications technology products for the satellite communications, space, telecommunications (5G/6G) and military defense markets Markets analysts forecast continued growth over the next five years in the RF component sector, with a CAGR of 13 percent in the multi-billion-dollar sector AmpliTech reported a 2021 Q2 55% YOY revenue increase A recent follow-on order from an existing global defense and aerospace customer evidences AmpliTech’s growth potential as it continues to build revenues and…

FridayAug 27, 2021 10:40 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Presents CBN-Based Treatment for Glaucoma at H.C. Wainwright Ophthalmology Virtual Conference

The presentation highlighted the company’s INM-088 cannabinol topical eye drop to treat glaucoma InMed’s IntegraSyn is being used to help the company develop synthetic bioidentical rare cannabinoids in the lab, as most are only found in trace amounts in cannabis plants In addition to INM-088 for glaucoma, the company is currently working on CBN-based INM-755 to treat a rare genetic skin disorder called epidermolysis bullosa and is awaiting the answer to Phase II trial applications in various countries Dedicated to delivering new therapeutic alternatives as a treatment for conditions with a high unmet medical need, InMed Pharmaceuticals (NASDAQ: INM) is…

FridayAug 27, 2021 10:08 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Set to Announce Q2 2021 Results on August 30, 2021

Red White & Bloom Brands Inc. is set to release its Q2 2021 financial results on Monday, August 30, 2021 The announcement will also be followed by an update on the company’s asset purchases, accompanying notes along with management discussion and analysis Q1 2021 saw outstanding performance for the company, with the CEO announcing intentions to finalize its revised asset purchase of the Michigan investee The August 30 announcement will give an update to this and more investment decisions for Q2 2021 On July 27, 2021, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) announced its 2021 1st quarter…

FridayAug 27, 2021 9:00 am

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Signs Alliance to Evaluate Potential Production of Isotopes for Emerging Cancer Therapeutics

UUUU, RadTran to study the recovery of thorium, radium, from existing rare earth carbonate and uranium process streams The alliance has the potential to develop commercial technologies and sources of isotopes needed for a new domestic medical supply chain Partnership aims to alleviate major bottleneck in the targeted alpha therapy market Due to its highly unique licenses, capabilities, and expertise, Energy Fuels (NYSE American: UUUU) (TSX: EFR) is able to supply critical minerals and materials that no other company in the U.S. – or possibly outside of China – is able to do. Energy Fuels’ business revolves around its ability…

Site Search

Company Search

Category: News